Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
$250 is come before ER
-
$250 before ER
-
Buy buy buy buy
-
This is the new ATH on regular hrs. The ATH was on January 29th pre-market, it was $218.45
-
Let’s close at or over $195 please
-
The lis kind of movement is due to short covering which means buying on the new high
-
Buy buy buy, this is going to explode
-
Shorts are covering or bringing more money to the table to cover margins calls
-
As soon we cross the $200, we will be in the $300 in no time
-
We need to leave the last ATH of $189 behind, otherwise shorts will fight hard to keep it below.
-
In power hr we might make it a 20% since last Friday
-
This was a bad week for shorts. $MRNA is up 15% since last Friday
-
In the last hr we will see the ATH $189. That is due to shorts not wanting to hold over the long weekend and loosing more money. Next week we will see the $200s for the first time in regular hrs.
-
Last earnings would have been at the $250 if it wasn’t for the intelectual property protection news. That was so well planned that made the big earnings report worthless. But this coming ER should be even better and finally we might even see the $300
-
The ATH was $218.45 in the pre-market hrs of January 29th
-
I just want to see again the $216 of the January 29 PRE market price.
With the kind of money $MRNA is making, it should be in the $300s. That is just based on Covid vaccines sales, but as soon they get another vaccine approved which they will. It is game over.
-
-
$BNTX is being held back by weak-hearted, “clay-handed” investors who simply don’t have enough belief to hold on to their shares despite all the fantastic news and great numbers being reported by the company. They keep selling, either taking profit on small upticks or panic-selling on the slightest negative news. If only $BNTX shareholders had “diamond-hands” like the punters driving $GME up for no rhyme or reason! Even the level of belief that $NVAX buyers are showing despite no actual vaccine being in the market would be sufficient to drive $BNTX to the moon. And there is simply no reason why $MRNA should have a market valuation that is 1.5x $BNTX. Parity with $MRNA itself should drive the price to $300+.
-
Guys great news!,,️️ https://apple.news/ASGpi30H3QT-Bqjl8aX-LDA
-
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more (NYSE:OXM)
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •